How Does Mach7 Technologies (ASX:M7T) Expand Its Footprint With Temple Health?

Sonal Goyal

13 November 2026 12:05 PM AEDT

How Does Mach7 Technologies (ASX:M7T) Expand Its Footprint With Temple Health?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Temple Health has signed a five-year subscription licence for Mach7’s eUnity Viewer and Vendor Neutral Archive.
The contract is effective from 30 October 2026, with first-year annual Recurring Revenue of A$0.5 million expected after go-live.
First productive use is expected within six to twelve months.
The ARR figure assumes an AUD/USD Exchange Rate of $0.68.

Mach7 Technologies Limited (ASX:M7T) has announced a new customer contract with Temple Health, a Philadelphia-based academic health system. The enterprise imaging software provider will Supply its eUnity Viewer and Vendor Neutral Archive under a five-year term. The company says the arrangement adds to its presence in academic health systems and integrated delivery networks.

Contract Scope and Revenue Expectations

Mach7 expects the contract to initially contribute A$0.5 million to annual recurring revenue. That estimate assumes an AUD/USD exchange rate of $0.68. The company defines ARR as annual recurring revenue and says first productive use, a term it uses to describe the point at which the system is in active clinical use, is expected within six to twelve months. The contract is effective from 30 October 2026, but the company has indicated that the revenue figure is expected to be realised after go-live.

Because the revenue is contracted on a subscription basis across five years, the company describes the arrangement as recurring rather than a one-time licence sale. The ARR figure refers to the first year and does not capture the full five-year value of the agreement. The announcement does not disclose total contract value, pricing structure or the timing of revenue recognition in each reporting period.

Temple Health and the Products Deployed

Temple Health operates 990 licensed beds, more than 1,700 physicians and more than 350 researchers. Its network includes the main campus of Temple University Hospital in North Philadelphia, the Jeanes, Episcopal and Northeastern campuses, Temple Health-Chestnut Hill Hospital and Fox Chase Cancer Centre, an NCI-designated comprehensive cancer centre. The health system’s recognised programs include organ transplantation, lung and thoracic medicine, cardiovascular medicine, neurosciences, orthopaedics, gastroenterology, oncology and urology.

Mach7 is providing its eUnity Viewer, which the company describes as an enterprise diagnostic viewer, together with its Vendor Neutral Archive. The company describes the platform as designed to help healthcare organisations manage, access and share diagnostic imaging data across complex environments. Mach7 has also said its platform is increasingly aligned with cloud ecosystems including Amazon Web Services and Oracle Cloud Infrastructure, and that it is expanding a suite of Flamingo modules across workflow and interoperability.

Management Commentary

Mach7 Chief Executive Officer and Managing Director Teri Thomas said the Partnership is intended to help Temple Health clinicians access the imaging information they need across hospitals and specialty centres. She said connected imaging can support better-coordinated care for patients whose treatment involves multiple teams. Thomas also described the agreement as part of a broader focus on solving practical challenges for clinicians in academic health systems and integrated delivery networks.

The announcement places the contract within Mach7’s wider product range. The company describes its platform as combining a Vendor Neutral Archive, the eUnity Enterprise Diagnostic Viewer and a growing set of Flamingo modules that address workflow, interoperability and data management. Mach7 has said these capabilities are designed to help healthcare organisations build a longitudinal patient record that brings diagnostic imaging together with broader clinical data. The Temple Health contract covers two of these components, the viewer and the archive, rather than the full suite. The company’s forward-looking statement notes that its expectations are based on current assumptions and that outcomes may differ from those described.

Closing Perspective

The announcement sets out a five-year contract and an initial ARR estimate for the first year, with the revenue dependent on go-live and the progression to first productive use. The company’s future disclosures are likely to indicate when the contract begins contributing revenue and whether the Temple Health deployment expands within its network. Investors and readers following the company’s healthcare software Business will have a clearer view of the contract’s contribution once go-live is confirmed.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.